IVBXF News & Events

Innovent Biologics announced that it has been successfully added as a constituent stock of the Hang Seng Index, HSI, following the release of the Q3 2025 Hang Seng Index Series Quarterly Review results, joining the ranks of blue-chip companies representing Hong Kong's core assets. "This milestone makes Innovent the first company that has grown from a biotech into a leading biopharma and been included in the HSI," the company said. The company has been concurrently admitted to the Hang Seng China Enterprises Index, HSCEI, and the Hang Seng ESG Enhanced Index.

Innovent Biologics jointly announced with Sanegene Bio USA that the preliminary results from the first-in-human, FIH, Phase 1 clinical study of IBI3016, an experimental small interfering RNA, siRNA, medicine targeting angiotensinogen mRNA, AGT, were reported at the 2025 American Heart Association, AHA, scientific sessions. Dr. Fangfang Wang from Peking University Third Hospital, delivered the moderated digital poster presentation of the study results. IBI3016 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous administration. The clinical Phase 1 data of IBI3016 further support the potential for biannual subcutaneous dosing for the treatment of hypertension. Next-step development is scheduled to initiate soon.

Innovent Biologics (IVBXF) announced a strategic global collaboration with Takeda (TAK) to advance next-generation IO and ADC cancer therapies, with the goal of developing potentially transformative cancer treatments to benefit patients worldwide. This partnership aims to leverage key synergies and accelerate the global development of several investigational medicines within Innovent's IO+ADC pipeline, including: IBI363, a first-in-class PD-1/IL-2alpha-bias bispecific antibody fusion protein demonstrating robust anti-tumor activity and potential to be a foundational next-generation IO therapy that is currently in Phase 3 clinical stage; IBI343, a potentially best-in-class CLDN18.2 ADC currently in Phase 3 clinical stage; and IBI3001, a first-in-class EGFR/B7H3 bispecific ADC currently in Phase 1 clinical stage. According to the agreement, Innovent and Takeda will co-develop IBI363 globally, sharing development costs 40/60 (Innovent/Takeda). In the U.S., Innovent and Takeda will co-commercialize IBI363, sharing the U.S. profit or loss 40/60. Takeda will lead the co-development and co-commercialization efforts under joint governance and aligned development plan. In addition, Innovent will grant Takeda commercialization rights outside Greater China and the U.S. Takeda will have global manufacturing rights to supply IBI363 outside of Greater China, with such rights being co-exclusive with Innovent for commercial supply in the U.S. Takeda will pay Innovent potential development and sales milestones outside Greater China, and tiered royalties up to high-teens on net sales outside Greater China and the U.S.

Innovent Biologics announced that multiple exploratory mechanism-of-action analyses of mazdutide as well as a preclinical study of IBI3030 will be showcased at the American Diabetes Association's, ADA, 85th Scientific Sessions. The presentations include the following: Title: A novel antibody-peptide conjugate targeting PCSK9, GLP-1R, GCGR, GIPR improves cardiovascular risk markers in preclinical study. Topic: The Dual Glucagon and Glucagon-Like Peptide 1 Receptor Agonist Mazdutide Outbalanced Glucagon-Like Peptide 1 Receptor Agonist Semaglutide Monotherapy in Improving Mice Liver Fat Accumulation. Topic: Mazdutidea GCG/GLP-1R dual-agonist, alleviates MASH and hepatic fibrosis. Topic: Mazdutide, a Dual GLP-1R/GCGR Agonist, Alleviates Hyperuricemia by Modulating Hepatic Energy and Lipid Metabolism and Inhibiting Purine Pathways.